Dyad Medical, Inc. Joins the Japan External Trade Organization

The cardiac imaging platform developer seeks expansion in global market

Dyad Medical, Inc., the Boston-based developer of the cloud-based AI technology for cardiac image analysis called Libby®, has joined the Japan External Trade Organization (JETRO) as it looks to expand into global markets.

This acceptance into the program comes shortly after Dyad Medical received FDA clearance for its Intravascular Optical Coherence Tomography (IVOCT) image analysis module.

With its association with JETRO, Dyad Medical aims to connect with potential investors and other partners in Japan and other countries in Asia. JETRO, a non-profit organization that helps businesses successfully enter the Japanese market, offers resources for businesses to partner with various organizations, investors and other healthcare partners. These partnerships will allow Dyad Medical to expand its efforts in the adoption of imaging AI in high quality patient care.

“Dyad Medical’s Intravascular OCT app, Libby® IAAA, recently received FDA clearance,” said Ronny Shalev, PhD., CEO and Co-Founder of Dyad Medical. “We are enhancing our FDA application to provide more clinical validation and our association with JETRO will help us further broaden the adoption of imaging AI as an integral part of value-based care.”

Libby® IAAA is a groundbreaking AI and cloud-based healthcare technology for cardiovascular imaging analysis. With this technology, Dyad Medical, Inc. aims to enable doctors to interpret medical image content more efficiently from anywhere in the world. Libby® is powered by artificial intelligence, as a global community of clinicians have shared their expertise to train the AI model, effectively offering practitioners “thousands of second opinions.”

About Dyad Medical
Boston-based Dyad Medical develops clinical applications using cloud-based artificial intelligence aimed at enabling doctors to interpret medical image content more efficiently from anywhere in the world. It is powered by the expertise of a global community of clinicians who train the model, effectively offering practitioners “thousands of second opinions.” Within the digital diagnostics arena, Dyad Medical’s core focus is on cardiac imaging because more people die as a result of cardiovascular disease than all types of cancer, diabetes, and accidents combined.

About JETRO
The Japan External Trade Organization (JETRO) is a non-profit organization that provides business support services to companies expanding to Japan. Since 2003, JETRO has supported more than 15,000 business investment projects and helped over 1,500 companies successfully invest in Japan. With the support of JETRO’s dedicated staff, clients can incorporate their business; receive visa, immigration, and HR support; find dedicated office space; identify local government subsidies; get tailored market studies; and more.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”